IP Library Granted Patent US 8,093,354
Granted Patent B2
US 8,093,354 · App. 12/759,076 · Granted Jan 10, 2012

Process for preparing glycopeptide phosphonate derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,093,354
App. No.
12/759,076
Granted
Jan 10, 2012
Kind
B2
Abstract

Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process.

Claims (53)

1. A process for preparing a compound of formula I:

wherein

R 1 is selected from the group consisting of C 1-10 alkylene, C 2-10 alkenylene and C 2-10 alkynylene;

R 2 is selected from the group consisting of C 1-20 alkyl, C 2-20 alkenyl, C 2-20 alkynyl, C 3-8 cycloalkyl, C 5-8 cycloalkenyl, C 6-10 aryl, C 2-9 heteroaryl, C 2-9 heterocyclic, —R a —Cy 1 , —R a —Ar 1 —Ar 2 , —R a —Ar 1 —R b —Ar 2 , and —R a —Ar 1 —O—R b —Ar 2 ;

R 4 is C 1-10 alkylene;

R a is selected from the group consisting of C 1-10 alkylene, C 1-10 alkenylene and C 1-10 alkynylene;

R b is selected from the group consisting of C 1-6 alkylene, C 1-6 alkenylene and C 1-6 alkynylene;

Cy 1 is selected from the group consisting of C 3-8 cycloalkyl, C 5-8 cycloalkenyl, C 6-10 aryl, C 2-9 heteroaryl, and C 2-9 heterocyclic;

Ar 1 and Ar 2 are independently selected from C 6-10 aryl and C 2-9 heteroaryl;

wherein each aryl, heteroaryl and heterocyclic group is optionally substituted with 1 to 3 substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, halo, hydroxy, nitro and trifluoromethyl, and each heteroaryl and heterocyclic group contains from 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur;

or a salt thereof;

the process comprising:

(a) reacting vancomycin or a salt thereof, with a compound of formula II:

wherein R 1 and R 2 are as defined herein; and R 3 is a amine-labile protecting group; and a reducing agent to form a compound of formula III:

wherein R 1 , R 2 and R 3 are as defined herein, or a salt thereof;

(b) reacting the compound of formula III with an amine to provide a compound of formula IV:

wherein R 1 and R 2 are as defined herein, or a salt thereof; wherein step (a) and step (b) are conducted in the same reaction mixture without isolation of the intermediate from step (a);

(c) reacting the compound of formula IV with formaldehyde and a compound of formula V:

in the presence of a base at a temperature in the range from about −20° C. to about 20° C. to provide a compound of formula I, or a salt thereof.

2. The process according to claim 1 , wherein R 1 is C 1-6 alkylene.

3. The process according to claim 2 , wherein R 1 is —CH 2 —.

4. The process according to claim 1 , wherein R 2 is C 6-14 alkyl.

5. The process according to claim 4 , wherein R 2 is n-decyl.

6. The process according to claim 1 , wherein R 3 is a group of formula (A):

W—OC(O)—  (A)

wherein W is selected from the group consisting of 9-fluorenylmethyl, 3-indenylmethyl, benz[f]inden-3-ylmethyl, 17-tetrabenzo[a,c,g,i]fluorenylmethyl, 2,7-di-tert-butyl[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, and 1,1-dioxobenzo[b]thiophene-2-ylmethyl, wherein the 9-fluorenylmethyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of C 1-6 alkyl, halo, nitro and sulfo.

7. The process according to claim 6 , wherein W is 9-fluorenylmethyl, wherein the 9-fluorenylmethyl group is optionally substituted with 1 to 3 substituents selected from the group consisting of C 1-6 alkyl, halo, nitro and sulfo.

8. The process according to claim 7 , wherein W is 9-fluorenylmethyl.

9. The process according to claim 1 , wherein R 4 is C 1-6 alkylene.

10. The process according to claim 9 , wherein R 4 is —CH 2 —.

11. The process according to claim 1 , wherein the reducing agent in step (a) is amine/borane complex.

12. The process according to claim 11 , wherein the reducing agent in step (a) is pyridine/borane or tert-butylamine/borane.

13. The process according to claim 1 , wherein step (a) comprises the steps of:

(i) combining vancomycin or a salt thereof with a compound of formula II in the presence of base to form a reaction mixture;

(ii) acidifying the reaction mixture from step (i) with an acid; and

(iii) contacting the reaction mixture from step (ii) with a reducing agent.

14. The process according to claim 13 , wherein the base in step (i) is a tertiary amine.

15. The process according to claim 14 , wherein the base in step (i) is diisopropylethylamine.

16. The process according to claim 13 , wherein the acid in step (ii) is trifluoroacetic acid or acetic acid.

17. The process according to claim 1 , wherein the amine in step (b) is ammonium hydroxide or a primary amine.

18. The process according to claim 17 , wherein the amine in step (b) is ammonium hydroxide, methylamine or tert-butylamine.

19. The process according to claim 18 , wherein the amine in step (b) is tert-butylamine.

20. The process according to claim 1 , wherein the base in step (c) is a tertiary amine.

21. The process according to claim 20 , wherein the base in step (c) is diisopropylethylamine.

22. The process according to claim 20 , wherein the molar ratio of tertiary amine to compound of formula V is about 3:1 to about 5:1.

23. The process according to claim 22 , wherein the molar ratio is about 4:1.

24. The process according to claim 1 , wherein

R 1 is —CH 2 —;

R 2 is n-decyl;

R 3 is W—OC(O)—, where W is 9-fluorenylmethyl;

R 4 is —CH 2 —;

the reducing agent in step (a) is tert-butylamine/borane;

and the amine in step (b) is tert-butylamine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033180/0199 →